HLS Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLTRF research report →
About the company
HLS Therapeutics Inc. is a specialized pharmaceutical firm engaged in the acquisition and commercialization of medicinal products, with a primary focus on the central nervous system (CNS) and cardiovascular (CV) therapeutic areas. The company's activities extend across Canada, the United States, and international territories.
- CEO
- Craig Stuart Millian
- IPO
- 2010
- Employees
- 92
- HQ
- Etobicoke, ON, CA
Price Chart
- Market Cap
- $93.82M
- P/E
- -9.31
- P/S
- 1.68
- P/B
- 1.60
- EV/EBITDA
- 7.05
- Div Yield
- 0.00%
- Gross Margin
- 61.69%
- Op Margin
- -7.34%
- Net Margin
- -18.42%
- ROE
- -16.54%
- ROIC
- -3.66%
- Revenue
- $56.47M · -0.26%
- Net Income
- $-12,647,593 · 35.65%
- EPS
- $-0.40 · 35.48%
- Op Income
- $-4,177,877
- FCF YoY
- 97.91%
- 52W High
- $4.02
- 52W Low
- $2.98
- 50D MA
- $3.26
- 200D MA
- $3.43
- Beta
- 0.85
- Avg Volume
- 156
Get TickerSpark's AI analysis on HLTRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HLTRF coverage
Recent articles, reports, and earnings notes.
No research on HLTRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HLTRF report →Similar companies
Peers in the same neighborhood.